Rituximab-induced lung disease
The Medical Journal of Malaysia
;
: 209-210, 2016.
Artigo
em Inglês
| WPRIM
| ID: wpr-630806
ABSTRACT
Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been reported and may cause mortality despite early detection. Typically the pulmonary toxicity occurs at around the fourth cycle of Rituximab. High index of suspicion is crucial and other concurrent pathology such as infective causes should be excluded. Radiological imaging and histological confirmation should be obtained and early treatment with corticosteroid should be initiated. Patients should receive counselling regarding respiratory symptoms and possible pulmonary toxicity.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Rituximab
/
Pneumopatias
Tipo de estudo:
Estudo de rastreamento
Idioma:
Inglês
Revista:
The Medical Journal of Malaysia
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS